The litigation centers on claims that Microvast failed to disclose significant operational hurdles, including inventory management issues and delays in the Huzhou Phase 3.2 manufacturing expansion. According to the complaint, these omissions rendered the company's financial outlook and growth projections materially misleading to the market.

The alleged corrective disclosures culminated on March 16, 2026, when the company reported a sharp decline in gross margins to 1% and revenue that fell significantly short of consensus estimates. Following these disclosures, Microvast shares dropped approximately 34.2% on March 17, 2026, closing at $1.52 per share. Eligible shareholders may participate in the recovery process without incurring personal legal fees, as these costs are typically recovered from defendants should the action succeed.